A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard)

BACKGROUND. Capecitabine administered for 7 days biweekly with oxaliplatin (XELOX) biweekly has been reported to have activity and safety profiles similar to those of standard capecitabine given for 14 days triweekly. Multiple studies have shown that the addition of bevacizumab to 5-fluorouracil–bas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hurwitz, Herbert, Mitchell, Edith P., Cartwright, Thomas, Kwok, Ambrose, Hu, Sylvia, McKenna, Edward, Patt, Yehuda Z.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399650/
https://ncbi.nlm.nih.gov/pubmed/22622147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados